ENDRA Life Sciences Inc. Form 8-K Summary
Business Context and Reporting Period
ENDRA Life Sciences Inc. (NDRA), a Delaware corporation, filed this Current Report on Form 8-K on August 17, 2026. The filing serves to announce the Company's financial results for the quarter ended June 30, 2026, via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the referenced press release (Exhibit 99.1) and are not included in the body of this Form 8-K.
Material Changes
The filing does not disclose specific material changes versus the prior comparable period. It only confirms the issuance of results for the quarter ended June 30, 2026.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The document explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 17, 2026) for actual financial figures and operational highlights.
- Verify the specific revenue and net loss figures for the quarter ended June 30, 2026, as they are not listed in this summary document.
- Check for any updated cash runway or liquidity position details in the full press release.
- Confirm if the press release includes any revised full-year 2026 guidance.